Q32 Bio Inc. (QTTB) — SEC Filings
Q32 Bio Inc. (QTTB) — 42 SEC filings. Latest: 10-Q (May 5, 2026). Includes 20 8-K, 6 10-Q, 3 SC 13G/A.
View Q32 Bio Inc. on SEC EDGAR
Overview
Q32 Bio Inc. (QTTB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 30, 2026: Q32 Bio Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The company, headquartered in Waltham, MA, is involved in the pharmaceutical preparations industry, specifically within Life Sciences.
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Q32 Bio Inc. is neutral.
Filing Type Overview
Q32 Bio Inc. (QTTB) has filed 6 10-Q, 20 8-K, 1 ARS, 1 DEFA14A, 1 DEF 14A, 2 10-K, 3 SC 13G/A, 2 SC 13G, 1 S-1, 1 10-K/A, 3 SC 13D, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of QTTB's 29 recent filings, 2 were flagged as high-risk, 20 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$70.1M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Elias P. Rosenblatt
- Dr. Michael J. Yauch
- Paul Alloway
- Jodie Morrison
- Albert Seymour
- Anders Hove
- Adriana Schwartz, Esq.
Industry Context
The pharmaceutical preparations industry, particularly the segment focused on autoimmune diseases, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies in this space often operate at a loss for extended periods, relying on substantial capital raises to fund clinical trials and eventual commercialization. The competitive landscape is intense, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Top Tags
biotech (6) · 8-K (4) · 10-Q (4) · financials (4) · merger (4) · acquisition (4) · SEC Filing (3) · Biotechnology (3) · corporate-governance (3) · delisting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| PDF Size | 4471494 | Size of the primary ARS document |
| Text File Size | 6159077 | Size of the complete submission text file |
| Filing Date | 2026-04-30 | Date of the DEFA14A filing |
| SEC File Number | 001-38433 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 47-3468154 | Company's tax identification number. |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Net Loss | $35.4M | for the three months ended June 30, 2025, an increase from $28.1M in 2024 |
| Research and Development Expense | $29.8M | for the three months ended June 30, 2025, reflecting clinical trial investment |
| General and Administrative Expense | $5.6M | for the three months ended June 30, 2025 |
| Reporting Period End Date | 2025-03-31 | Indicates the financial period covered by the 10-Q filing. |
| Loan Agreement Date | 2020-12-11 | Marks the execution date of the loan and security agreement with Silicon Valley Bank. |
| Fiscal Year End | 2023-12-31 | Reporting period for executive compensation |
| Reporting Period End | 2024-09-30 | The 10-Q covers financial data up to this date. |
| Standard Industrial Classification | 2834 | Pharmaceutical Preparations |
| Prior Fiscal Year End | 2022-12-31 | Prior fiscal year end for which data is referenced |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Q32 Bio Inc. (QTTB)?
Q32 Bio Inc. has 42 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QTTB filings?
Across 42 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Q32 Bio Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Q32 Bio Inc. (QTTB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Q32 Bio Inc.?
Key financial highlights from Q32 Bio Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QTTB?
The investment thesis for QTTB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Q32 Bio Inc.?
Key executives identified across Q32 Bio Inc.'s filings include Dr. Elias P. Rosenblatt, Dr. Michael J. Yauch, Paul Alloway, Jodie Morrison, Albert Seymour and 2 others.
What are the main risk factors for Q32 Bio Inc. stock?
Of QTTB's 29 assessed filings, 2 were flagged high-risk, 20 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Q32 Bio Inc.?
Forward guidance and predictions for Q32 Bio Inc. are extracted from SEC filings as they are enriched.